search
Back to results

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (IMPACT)

Primary Purpose

Dry Eye Syndromes

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
cyclosporine 0.05% ophthalmic emulsion
carboxymethylcellulose-based lubricant eye drops
Sponsored by
Allergan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry Eye Syndromes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • History of dry eye in both eyes
  • Willing to use eye drops for dry eye symptoms

Exclusion Criteria:

  • Anticipate wearing contact lenses during the study
  • Laser-assisted in situ keratomileusis (LASIK) surgery within the past 12 months
  • Any ocular and/or lid surgeries within the past 6 months
  • Cataract surgery in either eye
  • Current or anticipated use of temporary punctal plugs during the study

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

cyclosporine 0.05% ophthalmic emulsion

Arm Description

Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.

Outcomes

Primary Outcome Measures

Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye
Total corneal staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Corneal Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye
Total conjunctival staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye
Total corneal staining with lissamine green is measured in the worse eye utilizing the Ora CalibraTM Corneal Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye
Total conjunctival staining with lissamine is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The reading question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The reading score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Change From Baseline in Driving at Night on the OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The driving at night question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The driving at night score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Change From Baseline in Working With a Computer or Bank Machine on the OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The working with a computer or bank machine question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The working with a computer or bank machine score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Change From Baseline in Watching TV on the OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The watching TV question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The watching TV score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Change From Baseline in Reading Rate
Reading speed is assessed as the number of words read correctly in 2 minutes.
Change From Baseline in Words Read Incorrectly
The numbers of words read incorrectly are counted in 2 minutes. A positive change from baseline indicates a worsening, and a negative change from baseline indicates an improvement.
Change From Baseline in Font Size
The minimum font (letter) size read correctly is assessed. Smaller font size indicates better ability. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Secondary Outcome Measures

Change From Baseline in OSDI
The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Change From Baseline in Ocular Discomfort on a 4-point Scale
Ocular discomfort is assessed on a 4-point scale where 0=no discomfort and 3=most discomfort. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
Change From Baseline in Tear Film Break-up Time in the Worse Eye
TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement and a negative number change from baseline indicates a worsening.
Change From Baseline in the Interblink Interval in the Worse Eye
The interblink interval measures the time (seconds) between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.
Change From Baseline in Conjunctival Redness in the Worse Eye
Conjunctival redness is scored in the worse eye on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.

Full Information

First Posted
April 22, 2014
Last Updated
April 9, 2019
Sponsor
Allergan
search

1. Study Identification

Unique Protocol Identification Number
NCT02121847
Brief Title
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
Acronym
IMPACT
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
April 3, 2014 (Actual)
Primary Completion Date
September 23, 2014 (Actual)
Study Completion Date
September 23, 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Allergan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Syndromes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
cyclosporine 0.05% ophthalmic emulsion
Arm Type
Experimental
Arm Description
Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Intervention Type
Drug
Intervention Name(s)
cyclosporine 0.05% ophthalmic emulsion
Other Intervention Name(s)
Restasis®
Intervention Description
Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
Intervention Type
Drug
Intervention Name(s)
carboxymethylcellulose-based lubricant eye drops
Other Intervention Name(s)
Refresh OPTIVE® Advanced
Intervention Description
Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Primary Outcome Measure Information:
Title
Change From Baseline in Total Corneal Staining Score With Fluorescein in the Worse Eye
Description
Total corneal staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Corneal Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time Frame
Baseline, Month 6
Title
Change From Baseline in Total Conjunctival Staining Score With Fluorescein in the Worse Eye
Description
Total conjunctival staining with fluorescein is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Flourescein Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time Frame
Baseline, Month 6
Title
Change From Baseline in Total Corneal Staining Score With Lissamine Green in the Worse Eye
Description
Total corneal staining with lissamine green is measured in the worse eye utilizing the Ora CalibraTM Corneal Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time Frame
Baseline, Month 6
Title
Change From Baseline in Total Conjunctival Staining Score With Lissamine Green in the Worse Eye
Description
Total conjunctival staining with lissamine is measured in the worse eye utilizing the Ora CalibraTM Conjunctiva Lissamine Staining Scale (0 to 4 scale where 0=no staining and 4= severe staining). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). A negative change from baseline represents a decrease in staining (improvement). A positive change from baseline represents an increase in staining (worsening).
Time Frame
Baseline, Month 6
Title
Change From Baseline in Reading on the Ocular Surface Disease Index (OSDI)
Description
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The reading question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The reading score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Driving at Night on the OSDI
Description
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The driving at night question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The driving at night score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Working With a Computer or Bank Machine on the OSDI
Description
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The working with a computer or bank machine question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The working with a computer or bank machine score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Watching TV on the OSDI
Description
The OSDI consists of 12 questions measuring the presence of ocular symptoms. The watching TV question is assessed using a 5-point scale (0=none of the time; 4=all of the time). The watching TV score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI reading scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Reading Rate
Description
Reading speed is assessed as the number of words read correctly in 2 minutes.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Words Read Incorrectly
Description
The numbers of words read incorrectly are counted in 2 minutes. A positive change from baseline indicates a worsening, and a negative change from baseline indicates an improvement.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Font Size
Description
The minimum font (letter) size read correctly is assessed. Smaller font size indicates better ability. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Time Frame
Baseline, Month 6
Secondary Outcome Measure Information:
Title
Change From Baseline in OSDI
Description
The OSDI consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (0=none of the time; 4=all of the time). The score is converted to a 0-100 score where 0 is best and 100 is worst. Higher OSDI scores are associated with greater severity. A negative number change from baseline indicates improvement and a positive number change from baseline indicates worsening.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Ocular Discomfort on a 4-point Scale
Description
Ocular discomfort is assessed on a 4-point scale where 0=no discomfort and 3=most discomfort. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Tear Film Break-up Time in the Worse Eye
Description
TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A positive number change from baseline indicates improvement and a negative number change from baseline indicates a worsening.
Time Frame
Baseline, Month 6
Title
Change From Baseline in the Interblink Interval in the Worse Eye
Description
The interblink interval measures the time (seconds) between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.
Time Frame
Baseline, Month 6
Title
Change From Baseline in Conjunctival Redness in the Worse Eye
Description
Conjunctival redness is scored in the worse eye on a numeric analog scale ranging from 0=None to 4=Extremely Severe (0.5 increments were allowed). A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.
Time Frame
Baseline, Month 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: History of dry eye in both eyes Willing to use eye drops for dry eye symptoms Exclusion Criteria: Anticipate wearing contact lenses during the study Laser-assisted in situ keratomileusis (LASIK) surgery within the past 12 months Any ocular and/or lid surgeries within the past 6 months Cataract surgery in either eye Current or anticipated use of temporary punctal plugs during the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Allergan
Official's Role
Study Director
Facility Information:
City
Andover
State/Province
Massachusetts
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27257373
Citation
Stonecipher KG, Torkildsen GL, Ousler GW 3rd, Morris S, Villanueva L, Hollander DA. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016 May 13;10:887-95. doi: 10.2147/OPTH.S101627. eCollection 2016.
Results Reference
background

Learn more about this trial

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

We'll reach out to this number within 24 hrs